Integrated Chinese and western medicine plays a unique role in the prevention and treatment of coronavirus disease 2019(COVID-19). At the same time, a lot of clinical research of Chinese medicine have been registered in China. A series of problems of scientific nature, standardization, and operability became emerging and disputed. The clinical researches should be conducted with overall consideration of the characteristics of Chinese medicine R & D, the dynamic epidemic condition and the scientific basis. Reasonable clinical indication is the key to the development of Chinese medicine against COVID-19, based on the collection of front-line reliable Chinese medicine diagnosis and treatment information. With the patient’s maximum benefit as the core and under the premise of not affecting the epidemic prevention and control, operable and adaptable clinical research protocols are needed with scientific and ethical consideration. The scientific supervision system should also be established for emergency conduct of clinical trials of new Chinese medicines in major emerging public health events. Taken together, real and reliable research results of effectiveness and safety of Chinese medicines are anticipated by scientific and rigorous clinical researches.